The conference was held by BI company at Le Méridien Taichung.

The medication used in the case sharing were mostly from BI company.

The speakers and moderators were all expertise in diabetes and kidney disease.

Dr. Tu from Ray Tong Clinic shared 5 cases with diabetes and kidney disease.

To protect the privacy of the patients, only important thinking process and treatment courses are shared in the page.

The patient has the history T2D for more than 5 years.

He also has the history of CAD s/p PCI.

He came to our clinic due to poor glucose control after 3 classes of medication used recently.

According to the rules of reimbursement system, after more than 6 months of linagliptin(DPP-4 i) use with HbA1c still above 7.5%, it was shifted to glyxambi (DPP-4 i+ SGLT2 i).

Follow-up HbA1c got improved after the adjustment.

Due to a few episodes of sense of hungry and suspected hypoglycemia, Amaryl-M was down titrated to half dosage.

(Amaryl-M is the combination of SU and metformin, among which SU has the risk of hypoglycemia)

Improved ACR was also noted after better glucose control and use of SGLT2 inhibitor.

(uACR: urine albumin-creatinine ratio)